首页> 外文期刊>European neurology >Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
【24h】

Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.

机译:Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.

获取原文
获取原文并翻译 | 示例
           

摘要

Forty patients affected by severe Parkinson's disease (PD) were treated with tolcapone as an adjunctive therapy to L-DOPA, for 3-7 months, until this drug was discontinued because of side-effects (2 diarrhoea, one of them with orthostatic hypotension, 2 increments of liver enzymes) or because of mandatory indications of the European drugs authority. All patients, after 3-6 months of L-DOPA therapy adjustments, received entacapone for 3 months again followed by withdrawal. L-DOPA daily dosage was significantly reduced by tolcapone and entacapone (p = 0.01 and 0.05). "On" time was increased by 15 during tolcapone treatment (p < 0.05), and by 8 during entacapone treatment. "Off" time was decreased by 16 during tolcapone and by 7 during entacapone treatment. Entacapone was withdrawn in the same patient who experienced diarrhoea and orthostatic hypotension during tolcapone because of recurrence of side-effects, in 6 patients because of increment of dyskinesias (with hallucinations) and in 1 patients because of rhythmic, jerking myoclonus. Copyright 2001 S. Karger AG, Basel

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号